NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury

Positive

AI Analysis

Summary

NovaGo Therapeutics closed a USD 30 million Series B financing round led by Neurimmune and Pureos to advance a proof-of-concept study in acute spinal cord injury, with additional non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.

Clinical Trial Data

Phase

proof-of-concept

Importance:5/10

Sentiment:

0.70

Series B financingspinal cord injuryproof-of-concept studycapital raise

Read the original article

Published by PR Newswire Biotech on September 2, 2026 10:00 AM

Read Original